British-Swedish pharma giant, AstraZeneca, has disclosed key preclinical data for AZD5305, its next-generation PARP1 selective inhibitor at the virtual American Association of Cancer Research (AACR) meeting this week.
Precigen claims breakthroughs in CAR T cell therapy manufacturing that will eventually allow cancer centers to enable treatments earlier and at a lower cost.
Thanks to a £2.7m (€3.9m) access fund from the UK's National
Biomanufacturing Centre (NBC), biotech firm Onyvax has hired
contract manufacturer organisation (CMO) Eden Biodesign to supply
it with clinical current good manufacturing...
Researchers in the US have found that blocking the COX-1, not COX-2
enzyme, might lead the way to prevent and treat the most common and
fatal form of ovarian cancer.
